From Biotech Startup to Stock Market | Paul Romness, MHA, Health Policy OS Therapies, CEO

Can a small biotech change cancer care—and turn a profit? Paul Romness, CEO of OS Therapies, shares how his five-person team took on one of the deadliest pediatric cancers, went public, and might just shake up the system. From biologics to Wall Street, this one’s got it all. Sponsored by Dae Lee of Buchanan.